Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

01_27_22 JP Morgan 2022

JP Morgan 2022 - Key Trends and Takeaways 

JP Morgan 2022 - Key Trends and Takeaways

Summary

Speakers

Matt Wetzel

Related Content

Biocon’s Pertuzumab Biosimilar Receives Positive CHMP Opinion Under EMA’s Tailored Clinical Approach

Nektar v. Lilly: Lilly Defeats CRE Claim, but Jury Finds It Owes $90M for Breaching the Implied Covenant of Good Faith and Fair Dealing

Preliminary Injunctive Relief in Trade Secret Cases: When to Move and What to Prove

Janssen Granted Preliminary Injunction Against Golimumab Biosimilar

STADA and SBP Group Launch Biosimilars Partnership

GLOBE Most Favored Nations Drug Pricing Model for Medicare Part B Drugs Finalized and Scaled Down by CMS

USPTO Institutes Four IPRs Challenging Janssen’s Golimumab Method-of-Treatment Patents

Dualitas Therapeutics and Roche Enter Research Collaboration to Discover and Develop Bispecific Antibodies

Goodwin Advises BioGeneration Ventures, Angelini Ventures, and Kurma Partners on $58 Million Series A Financing of RougeTx

Goodwin Advises Repligen Corporation on the Acquisition of BioLife Solutions

Goodwin Advises Alentis on Global Collaboration Agreement With CSL for $355 Million Upfront and Up to $1.2 Billion in Milestone Payments and Worldwide Profit Share

Naomi Birbach and Alicia Palladino Named 2026 Managing IP Rising Stars

Second Annual AI & Drug Discovery Symposium: Revolutionizing the Future of Medicine

Goodwin Advises Hengrui on Intellectual Property Aspects of Exclusive License Agreement with Novo for Up to $2.6 Billion

Goodwin Honors Partners Retiring at the Close of Fiscal Year 2026

The Legal 500 UK 2027 Highlights the Strength of Goodwin’s UK Platform

Life Sciences

Healthcare